NCT01037413已完成2 期
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF EXC 001 FOR THE AMELIORATION OF SCARRING FOLLOWING REVISION OF SCARS RESULTING FROM PRIOR BREAST SURGERY IN ADULT FEMALE SUBJECTS
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 25
- 试验地点
- 5
- 主要终点
- Expert Panel Scar Assessment Score at Week 12
研究概览
简要总结
This study will compare how well EXC 001 works to improve the appearance of scars in subjects undergoing breast scar revision surgery. The study will also evaluate the safety of EXC 001 in healthy adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Subjects must have previously had breast surgery resulting in unacceptable scars
- •Subject has chosen to have the breast scars revised
- •Subjects must not be pregnant or lactating
排除标准
- •Currently pregnant or pregnant during the 6 months prior to inclusion in the study, or lactating
- •Participation in another clinical trial within 30 days prior to the start of the study
- •Any other condition or prior therapy, which, in the opinion of the PI, would make the subject unsuitable for this study
研究组 & 干预措施
EXC 001
Experimental
干预措施: EXC 001 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Expert Panel Scar Assessment Score at Week 12
时间窗: Part B: Week 12
Scar assessment by an expert panel was done on blinded photographs using 100 millimeter (mm) visual analog scale (VAS) where a score of 0 mm = best possible scar and a score of 100 mm = worst possible scar, where higher scores indicate worse condition.
次要结局
- Expert Panel Scar Assessment Score at Week 8 and 24(Part B: Week 8 and 24)
- Physician Observer Scar Assessment Score at Week 12 and 24(Part B: Week 12 and 24)
- Participant Observer Scar Assessment Score at Week 12 and 24(Part B: Week 12 and 24)
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)(Part A: Day 1; Part B, Active Dosing: Week 2 up to Week 13; Part B, Post Dosing: Week 13 to end of the study (Week 24))
- Number of Participants With Abnormal Physical Examination Findings(Screening (up to Day 21 prior to Day 1 of Part A), Part B: Day 1, Week 12)
- Number of Participants With Clinically Significant Findings in Laboratory Examinations(Screening (up to Day 21 prior to Day 1 of Part A), Part B: Day 1 up to Week 12)
- Number of Participants With Clinically Significant Findings in Vital Signs(Screening (up to Day 21 prior to Day 1 of Part A), Part B: Day 1 up to Week 12)
- Number of Participants With Clinically Significant Findings in Electrocardiogram (ECG)(Screening (up to Day 21 prior to Day 1 of Part A), Part B: Week 12)
- Number of Participants With Positive Skin Sensitivity Reaction(Part A: Day 1, Part B: Week 2 up to Week 24)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective AbdominoplastyScar PreventionNCT01037985Pfizer41
已完成
2 期
Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective AbdominoplastyScar PreventionNCT01038297Pfizer30
已完成
2 期
Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast SurgeryReduction in Hypertrophic Skin ScarringNCT01346969Pfizer68
已完成
2 期
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision SurgeryReduction of Hypertrophic Skin ScarringNCT01730339Pfizer103
已完成
2 期
Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy MalesCicatrixNCT00594581Renovo71